Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

NEW YORK, May  26, 2020  (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the Company’s 2020 Annual Meeting of Stockholders will now be held in a virtual-only meeting format due to continued public health concerns resulting from the COVID-19 pandemic, government-recommended and required limits on public gatherings, and to protect the health and safety of the Company’s stockholders, directors, and employees.

Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually

Biogen

One biotech has been big long-time winner, the other is a promising up-and-comer with no revenue -- yet. But picking an investment is always a bet on the future.

Better Buy: Biogen vs. Axsome Therapeutics

Axsome Therapeutics: Sliding Share Price And FDA Approvals Highlight Gains

Just what exactly is going on with this company, which has had success in nearly every single clinical trial it initiated in recent years?

What's Behind Axsome Therapeutics' Miracle Pipeline?

Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.

Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses

Two positive late-stage clinical trials may just be the beginning.

Is Axsome Therapeutics a Screaming Buy?

Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q1 2020 Results - Earnings Call Transcript

argenx

Ascendis Pharma

Amicus Therapeutics

Iovance Biotherapeutics

Natera

United Therapeutics

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

7 “Strong Buy” Healthcare Stocks to Buy Now

Positive results from two pivotal trials helped this stock bounce back from a beatdown in March.

Here's Why Axsome Therapeutics Rocketed 61.5% Higher in April

Key details in an antidepressant's clinical trial may signal a revolutionary therapy for patients.

There May Be a New First-Line Treatment for Depression

An experimental drug could help caregivers as well as patients, as it substantially improved agitation in Alzheimer’s patients in a late-stage clinical trial.

Axsome Shares Jump 25% on Alzheimer’s Study Results

As there is currently no FDA-approved treatment for Alzheimer’s agitation, any progress here could be lucrative.

Why This Alzheimer’s Study Could Be Huge

Clinical trial results suggest that an experimental treatment combining two already-approved drugs could make life easier for Alzheimer's patients and their caregivers.

Drug Combination Helps Alzheimer's Disease Patients in Pivotal Study

Axsome Therapeutics Inc (NASDAQ: AXSM), which was a high-flier for most of 2019, has come off the all-time highs reached late last year thanks to the COVID-19 pandemic and a negative readout in late March.

Why Axsome Is Touching The $100 Level For The First Time In Months

The biotech reported positive news from a late-stage clinical study targeting Alzheimer's disease agitation.

Why Axsome Therapeutics Stock Is Skyrocketing Today

Dicerna Pharmaceuticals

These development-stage drug companies are well positioned for success, even amid the current market uncertainty.

2 Top Small-Cap  Stocks to Buy Right Now

Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.

Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study

Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002)

Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine

Adaptive Biotechnologies

Adaptive Biotechnologies and Axsome Therapeutics are under-followed stocks with large upsides.

2 Top Stocks That Aren't On  Wall Street's Radar

Horizon Pharma

MyoKardia

These drug developers just released new clinical trial results.

Should You Buy These 3 Biotechs Now?

Aerie Pharmaceuticals

bluebird bio

Puma Biotechnology

Pfizer

Rigel Pharmaceuticals

Success in clinical trials doesn't guarantee success on the market.

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.

Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study

Chemocentryx

DexCom

Eidos Therapeutics Inc

Enphase Energy

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

5 Guru Stocks That Beat the Market

The company's depression drug AXS-05 failed to meet its primary endpoints in the study, although it did hit the secondary endpoints.

Axsome Therapeutics' Key Drug Candidate Whiffs in Phase 3 Trial

An important clinical trial delivered mixed results.

News for Axsome Therapeutics Stock (AXSM)